Back

Preclinical immunogenicity of the LP.8.1-adapted BNT162b2 COVID-19 vaccine

Kurhade, C.; Chen, W.; Li, W.; Tompkins, K. R.; Martinez, L. T.; Rajput, S.; Babiarz, E.; Yam, A.; Lee, S.-A.; Shrivastava, S.; O'Leary, S.; Saha, S.; Yao, H.; Hao, L.; Coffey, T.; Couto, C. I. C.; Muik, A.; Moreno, R. M.; Swanson, W.; Daroca, P. M.; Sahin, U.; Anderson, A. S.; Swanson, K. A.; Allen, P. S.; Modjarrad, K.

2025-12-16 immunology
10.64898/2025.12.15.694478 bioRxiv
Show abstract

SARS-CoV-2 evolution toward antigenically distinct lineages drives escape from host immunity. JN.1 lineage derivatives have recently dominated the global epidemiologic landscape. In preclinical models, an LP.8.1-adapted BNT162b2 vaccine elicited higher serum neutralizing antibody responses against contemporary, circulating JN.1 sublineages, including the currently dominant XFG, as compared to JN.1-, KP.2- and XEC-adapted vaccines. These findings supported the selection of an LP.8.1-adapted vaccine for the composition of the 2025-26 COVID-19 vaccine formula.

Published in npj Vaccines (predicted rank #1) · training set

Matching journals

The top 3 journals account for 50% of the predicted probability mass.

npj Vaccines · published here
○ 67 papers in training set
Top 0.1%
30.3%
Similar papers in this journal
2
Nature Communications
○ 5641 papers in training set
Top 13%
14.7%
Similar papers in this journal
3
Nature Medicine
○ 125 papers in training set
Top 0.4%
5.0%
Similar papers in this journal
50% of probability mass above
4
eBioMedicine
○ 183 papers in training set
Top 0.8%
3.9%
Similar papers in this journal
5
The Lancet Infectious Diseases
○ 73 papers in training set
Top 0.3%
3.2%
Similar papers in this journal
6
Med
○ 39 papers in training set
Top 0.1%
3.1%
7
eLife
● 5828 papers in training set
Top 40%
2.7%
8
Frontiers in Immunology
○ 638 papers in training set
Top 5%
2.3%
9
Vaccine
○ 203 papers in training set
Top 1%
2.3%
10
Cell Reports
○ 1498 papers in training set
Top 18%
1.9%
11
Science Translational Medicine
● 127 papers in training set
Top 2%
1.5%
12
Molecular Therapy
○ 81 papers in training set
Top 1%
1.1%
13
Cell Reports Medicine
○ 153 papers in training set
Top 4%
1.1%
14
Nature
○ 645 papers in training set
Top 9%
1.1%
15
Science
● 477 papers in training set
Top 8%
1.0%
16
Emerging Microbes & Infections
○ 74 papers in training set
Top 1%
1.0%
17
Proceedings of the National Academy of Sciences
● 2444 papers in training set
Top 38%
1.0%
18
Science Advances
● 1243 papers in training set
Top 28%
1.0%
19
mBio
● 833 papers in training set
Top 10%
1.0%
20
Vaccines
○ 198 papers in training set
Top 3%
1.0%
21
Journal for ImmunoTherapy of Cancer
● 75 papers in training set
Top 2%
1.0%
22
Scientific Reports
○ 3612 papers in training set
Top 70%
1.0%
23
Cell
○ 431 papers in training set
Top 9%
0.9%
24
Science Immunology
● 88 papers in training set
Top 2%
0.8%
25
Molecular Therapy - Methods & Clinical Development
○ 38 papers in training set
Top 0.8%
0.6%
26
Nature Immunology
○ 79 papers in training set
Top 2%
0.6%
27
Cell Discovery
○ 57 papers in training set
Top 1%
0.6%
28
Microbiology Spectrum
● 469 papers in training set
Top 11%
0.6%
29
The Journal of Infectious Diseases
◐ 202 papers in training set
Top 4%
0.6%

"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.